| Year |
Citation |
Score |
| 2019 |
Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MM, Casanova-Salas I, Jibilian MC, Buckholtz CL, Ambrico AJ, Pan CH, Wilkinson JE, Newton AC, et al. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. The Journal of Cell Biology. PMID 31092557 DOI: 10.1083/Jcb.201902048 |
0.32 |
|
| 2018 |
D'Andrea V, Nowak D, Watrud K, Ambrico A, Casanova-Salas I, Trotman L. Abstract 1097: The Phlpp2 phosphatase protects Myc and is a target for the prevention of prostate cancer metastasis Cancer Research. 78: 1097-1097. DOI: 10.1158/1538-7445.Am2018-1097 |
0.381 |
|
| 2017 |
Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, et al. The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. The Journal of Cell Biology. PMID 28193700 DOI: 10.1083/Jcb.201604025 |
0.314 |
|
| 2015 |
Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, et al. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discovery. 5: 636-51. PMID 25829425 DOI: 10.1158/2159-8290.Cd-14-1113 |
0.321 |
|
| 2015 |
Nowak DG, Cho H, Herzka T, Wang VMY, Senturk S, DeMarco DV, Ding D, Fellmann C, Beinortas T, Kleinman D, Watrud K, Chen M, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, et al. Abstract 2258: Myc drives Pten/ p53-deficient proliferation and metastasis due to Il6-secretion and Akt-suppression via Phlpp2 Cancer Research. 75: 2258-2258. DOI: 10.1158/1538-7445.Am2015-2258 |
0.356 |
|
| 2014 |
Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proceedings of the National Academy of Sciences of the United States of America. 111: E3957-65. PMID 25201979 DOI: 10.1073/Pnas.1404221111 |
0.364 |
|
| 2014 |
Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3057-63. PMID 24928944 DOI: 10.1158/1078-0432.Ccr-12-3680 |
0.324 |
|
| 2011 |
Woolard J, Vousden W, Moss SJ, Krishnakumar A, Gammons MV, Nowak DG, Dixon N, Micklefield J, Spannhoff A, Bedford MT, Gregory MA, Martin CJ, Leadlay PF, Zhang MQ, Harper SJ, et al. Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. Chemical Science (Royal Society of Chemistry : 2010). 2011: 273-278. PMID 22822423 DOI: 10.1039/C0Sc00297F |
0.832 |
|
| 2011 |
Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20: 768-80. PMID 22172722 DOI: 10.1016/J.Ccr.2011.10.016 |
0.767 |
|
| 2011 |
Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell. 20: 173-86. PMID 21840483 DOI: 10.1016/J.Ccr.2011.07.013 |
0.305 |
|
| 2011 |
Naguib A, Nowak DG, Chen M, Trotman LC. Abstract 1269: Identifying Pten-sensitive drug therapy through metabolic phenotype-arrays Cancer Research. 71: 1269-1269. DOI: 10.1158/1538-7445.Am2011-1269 |
0.339 |
|
| 2010 |
Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ. Overexpression of VEGF165b in podocytes reduces glomerular permeability. Journal of the American Society of Nephrology : Jasn. 21: 1498-509. PMID 20688932 DOI: 10.1681/Asn.2009060617 |
0.512 |
|
| 2010 |
Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. The Journal of Biological Chemistry. 285: 5532-40. PMID 19906640 DOI: 10.1074/Jbc.M109.074930 |
0.765 |
|
| 2008 |
Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of Cell Science. 121: 3487-95. PMID 18843117 DOI: 10.1242/Jcs.016410 |
0.81 |
|
| 2007 |
Nowak DG, Amin E, Ladomery MR, Harper SJ, Bates DO. Selective upregulation of anti‐angiogenic splice variants of VEGF by TGF‐β1 is mediated by Cdc2‐like kinase family (Clk) and p38 MAPK The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A248-D |
0.612 |
|
| Show low-probability matches. |